Radiotherapy Access Alliance Files Suit Challenging Change in Evicore Guidelines
Radiotherapy Access Alliance Files Suit Challenging Change in Evicore Guidelines
PR Newswire
WINTER PARK, Fla., Nov. 16, 2026
WINTER PARK, Fla., Nov. 16, 2026 /PRNewswire/ -- For years, EviCore (a Franklin, TN, company) allowed low-dose radiation for patients with arthritis or heel pain when other treatments failed. On November 5, it reversed course. EviCore now calls the treatment "not medically necessary" for these and other conditions. A group of doctors and physicists has sued to stop the change.
The Alliance filed suit in Orange County Circuit Court on November 4. Rich Collins and his Washington, D.C., and Atlanta team at Arnall Golden Gregory, LLP, represent the group. The suit says EviCore has interfered with the relationship between doctors and their patients. It asks the court to rule on the parties' rights under Florida law. The Alliance seeks no damages.
On November 5, the Alliance asked the judge to block the new guidelines while the case proceeds. It wants EviCore to review each Florida patient's case under its February rules. EviCore could still deny a request if the patient fell short of those rules.
Health plans across the country hire EviCore to review the care doctors order. Its clients include Blue Cross, Aetna, Cigna and numerous other plans nationwide. EviCore helps those plans decide which treatments they will cover.
Since at least 2019, EviCore's rules specifically allowed LDRT for osteoarthritis and plantar fasciitis. In February 2026, EviCore deemed LDRT necessary and "associated with a response rate approaching 80% and durable at 48 weeks." On November 4, 2026, EviCore patients across the country with arthritis, bursitis, tendonitis or plantar fasciitis could still qualify for treatment. On November 5, EviCore's new guidelines rule LDRT out for almost everything (except a carve-out for tennis elbow) claiming a "paucity of evidence."
Evan Thomas, M.D., Ph.D., is a radiation oncologist in Winter Park and president of the newly formed non-profit Radiotherapy Access Alliance. The Alliance consists of radiation oncologists and physicists from several different states. "Our alliance, our specialty societies and other radiation companies tried to reach out to EviCore to get them not to reverse themselves, but those attempts didn't go anywhere. So we decided we had to sue."
About Radiotherapy Access Alliance, Inc.
The Radiotherapy Access Alliance (radiotherapyaccessalliance.org) is a Florida nonprofit founded in Winter Park in August 2026. It advocates for fair coverage of radiation therapy. Radiation oncologists, medical physicists, dosimetrists and radiation therapists can join as members. Patients whose treatment was denied or cut off can write to info@radiotherapyaccessalliance.org.
CONTACT: info@radiotherapyaccessalliance.org

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?

